UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000014460
Receipt number R000016826
Scientific Title Efficacy of Seprafilm for prevention of postoperative adhesions in repeat hepatectomy of recurrent liver tumors. Prospctive Randomized Controlled Trial
Date of disclosure of the study information 2014/07/11
Last modified on 2019/07/08 08:33:12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy of Seprafilm for prevention of postoperative adhesions in repeat hepatectomy of recurrent liver tumors.
Prospctive Randomized Controlled Trial

Acronym

Efficacy of Seprafilm in repeat hepatectomy of recurrent liver tumors.

Scientific Title

Efficacy of Seprafilm for prevention of postoperative adhesions in repeat hepatectomy of recurrent liver tumors.
Prospctive Randomized Controlled Trial

Scientific Title:Acronym

Efficacy of Seprafilm in repeat hepatectomy of recurrent liver tumors.

Region

Japan


Condition

Condition

hepatocellular carcinoma or colorectal liver metastases

Classification by specialty

Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effectiveness of Seprafilm for the prevention of the postoperative adhesions in liver surgery

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase III


Assessment

Primary outcomes

adhesion time needed for dissecting the adhesions in reoperation of the liver in future

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Single blind -participants are blinded

Control

No treatment

Stratification

YES

Dynamic allocation

YES

Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

application of Seprafilm after hepatectomy for the treatment of hepatocellular carcinoma or metastatic liver tumors.
No application of Seprafilm after hepatectomy for the treatment of hepatocellular carcinoma or metastatic liver tumors.

Interventions/Control_2

After hepatic resection, patients in both groups will undergo enhanced computed tomography every 3-4 months.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Age over 20 years old at the
registration day.
2) ECOG Performance Status is 0-2.
3) Patients with liver damage A or B
4) Patients with primary or secondary
hepatectomy scheduled for
hepatocellular carcinoma diagnosed by
CT imaging
5) Patients with primary or secondary
hepatectomy scheduled for the
treatment of colorectal liver
metastases in our department.
6) The history of prior local therapy are
permitted if liver tumor are
resectable.
7) Patients have enough organ function
for study treatment within 14 days
before registration.
- neutrophil count: >=2,000/mm3,
<=10,000 /mm3
- platelet: >=50,000/mm3
- serum bilirubib level: <=1.5mg/dL
- PT(%): >=50%
- serum creatinine level: <=1.5mg/dL
- AST: <=100IU/L
- ALT: <=100IU/L
- albumin: >=3.0g/dL
8) Written informed consent

Key exclusion criteria

1) Severe comorbidity
2) Severe infectious disease
3) Pleural effusion, ascites fluid and
the pericardial fluid needing treatment
4) Patients with other primary
malignancies.
5) A past history of drug allergy (needs
continuation therapy)
6) Chronic systemic treatment of
corticosteroid
7) Bleeding tendency, coagulation
disorder, abnormality of coagulation
factor, or administered anticoagulant
8) Patients infected with human
immunodeficiency virus (HIV)/acquired
immunodeficiency syndrome (AIDS).
9) Patients during pregnancy, breast-
feeding, or at risk of becoming
pregnant.
10) Psychological disorder
11) Considered not appropriate for surgery
12) Patients considered inappropriate by
the study investigator

Target sample size

1000


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takayama Tadatoshi

Organization

Nihon University School of Medicine

Division name

Department of Digestive Surgery

Zip code


Address

30-1, Ohyaguchi kami-machi, Itabashi-ku, Tokyo 173-8610, Japan

TEL

03-3972-8111

Email

takayama.tadatoshi@nihon-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Kanamoto Akira

Organization

Nihon University School of Medicine

Division name

Department of Digestive Surgery

Zip code


Address

30-1, Ohyaguchi kami-machi, Itabashi-ku, Tokyo 173-8610, Japan

TEL

03-3972-8111

Homepage URL


Email

kanamoto.akira@nihon-u.ac.jp


Sponsor or person

Institute

Department of Digestive Surgery, Nihon University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

KAKEN PHARMACEUTICAL CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Hepato-biliary-pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

日本大学医学部附属板橋病院(東京都)、東京大学医学部附属病院(東京都)


Other administrative information

Date of disclosure of the study information

2014 Year 07 Month 11 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2014 Year 05 Month 27 Day

Date of IRB

2014 Year 07 Month 11 Day

Anticipated trial start date

2014 Year 07 Month 11 Day

Last follow-up date

2019 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 07 Month 02 Day

Last modified on

2019 Year 07 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016826


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name